Rechercher

Résultats de recherche pour : « »

Somatic symptom disorder in patients with post-COVID-19 neurological symptoms: a preliminary report from the somatic study (Somatic Symptom Disorder Triggered by COVID-19).

Kachaner A, Lemogne C, Dave J, Ranque B, de Broucker T, Meppiel E. J Neurol Neurosurg Psychiatry. 2022 Aug 25:jnnp-2021-327899. doi: 10.1136/jnnp-2021-327899.
En savoir plus : Somatic symptom disorder in patients with post-COVID-19 neurological symptoms: a preliminary report from the somatic study (Somatic Symptom Disorder Triggered by COVID-19).
Long-lasting diagonistic dyspraxia suppressed by rTMS applied to the right motor cortex.

Sellal F, Cretin B, Musacchio M, Berthel MC, Carelli G, Michel JM. J Neurol. 2019 Mar;266(3):631-635. doi: 10.1007/s00415-018-09178-9. Epub 2019 Jan 10.
En savoir plus : Long-lasting diagonistic dyspraxia suppressed by rTMS applied to the right motor cortex.
Neurologic manifestations of giant cell arteritis.

Soulages A, Sibon I, Vallat JM, Ellie E, Bourdain F, Duval F, Carla L, Martin-Négrier ML, Solé G, Laurent C, Monnier A, Le Masson G, Mathis S. J Neurol. 2022 Jul;269(7):3430-3442. doi: 10.1007/s00415-022-10991-6. Epub 2022 Feb 6.
En savoir plus : Neurologic manifestations of giant cell arteritis.
Spinal cord tractopathy in paraneoplastic anti-CV2/CRMP5 myelitis responsive to plasma exchange.

Flabeau O, Laurent C, Schneider S, Honnorat J, Ellie E. Rev Neurol (Paris). 2022 Mar;178(3):280-282. doi: 10.1016/j.neurol.2021.04.009. Epub 2021 Jul 8.
En savoir plus : Spinal cord tractopathy in paraneoplastic anti-CV2/CRMP5 myelitis responsive to plasma exchange.
Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.

Manchon E, Laplaud D, Vukusic S, Labauge P, Moreau T, Kobelt G, Grouin JM, Lotz M, Pau D, Christine LF. Mult Scler Relat Disord. 2022 Dec;68:104109. doi: 10.1016/j.msard.2022.104109. Epub 2022 Aug 13.
En savoir plus : Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
Intravenous Thrombolysis Use in the Late Time Window Before Interhospital Transfer for Thrombectomy.

Seners P, Nehme N, Ter Schiphorst A, Charbonneau F, Chausson N, Belley M, Wacongne A, Kaaouana O, Henry C, Girbovan A, Bennani ON, Maïer B, Dupin M, Gerschenfeld G, Lun F, Marc G, Dassa J, Benoit T, Sablot D, Loeillot J, Rigal J, Smadja D, Scarcia L, Caroff J, Pico F, Henon H, Skerlak S,…
En savoir plus : Intravenous Thrombolysis Use in the Late Time Window Before Interhospital Transfer for Thrombectomy.
Transient ischemic attack care pathways in stroke units: Findings from a French nationwide survey.

Sablot D, Rivas Lamelo S, Renou P, Nasr N, Lavallee P, Plantard C, Blanc-Lasserre K, Domigo V, Sibon I, Béjot Y, Cordonnier C, Alamowitch S. Rev Neurol (Paris). 2025 Dec;181(10):998-1007. doi: 10.1016/j.neurol.2025.09.008. Epub 2025 Nov 4.
En savoir plus : Transient ischemic attack care pathways in stroke units: Findings from a French nationwide survey.
Direct oral anticoagulation versus no therapy or antiplatelet for stroke prevention in patients with atrial fibrillation and history of intracranial hemorrhage: a systematic review and meta-analysis.

Sablot D, Gaillard N, Belahsen F, Lamelo SR, Dumitrana A, Plantard C, Daghmouri MA, Chaouch MA. Front Med (Lausanne). 2025 Apr 25;12:1570809. doi: 10.3389/fmed.2025.1570809. eCollection 2025.
En savoir plus : Direct oral anticoagulation versus no therapy or antiplatelet for stroke prevention in patients with atrial fibrillation and history of intracranial hemorrhage: a systematic review and meta-analysis.
Becoming a thrombectomy-capable stroke center: Clinical and medico-economical effectiveness at the hospital level.

Checkouri T, Sablot D, Varnier Q, Fryder I, Collemiche FL, Azais B, Dargazanli C, Leibinger F, Cagnazzo F, Mahmoudi M, Lefevre PH, Van Damme L, Gascou G, Schmidt J, Arquizan C, Plantard C, Farouil G, Costalat V. Eur Stroke J. 2024 Dec;9(4):936-942. doi: 10.1177/23969873241254239. Epub 2024 May 17.
En savoir plus : Becoming a thrombectomy-capable stroke center: Clinical and medico-economical effectiveness at the hospital level.
Is off-label thrombolysis safe and effective in a real-life primary stroke center? A retrospective analysis of data from a 5-year prospective database.

Sablot D, Leibinger F, Dutray A, Van Damme L, Nguyen Them L, Farouil G, Jebali C, Arquizan C, Ibanez-Julia MJ, Laverdure A, Allou T, Chaabane W, Fadat B, Olivier N, Smadja P, Tardieu M, Lachcar M, Mas J, Ousji A, Jurici S, Mourand I, Ferraro A, Dumitrana A, Bensalah ZM, Damon F, Tincau OA, Valverde…
En savoir plus : Is off-label thrombolysis safe and effective in a real-life primary stroke center? A retrospective analysis of data from a 5-year prospective database.